Surgical outcomes after neoadjuvant avelumab with or without chemotherapy for Muscle-Invasive bladder cancer: a Post-Hoc analysis of the aura trial (Oncodistinct-004).

Fiche publication

Date publication

janvier 2026

Journal

World journal of urology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Dr TRICARD Thibault

Tous les auteurs :
Mjaess G, Quackels T, Fantoni JC, Tricard T, Marcq G, Blanc J, Barthelemy P, Carnot A, Sideris S, Awada A, Chanza NM, Peltier A, Albisinni S, Diamand R, Roumeguère T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41528535

Résumé

Neoadjuvant chemo-immunotherapy is emerging as promising strategy in muscle-invasive bladder cancer (MIBC), yet its perioperative safety remains understudied. This post-hoc analysis of the AURA phase-II trial assesses surgical outcomes following neoadjuvant avelumab with or without chemotherapy.